Aristotle Atlantic Partners LLC Lowers Stock Position in Bio-Techne Corp $TECH

Key Points

• Aristotle Atlantic Partners trimmed its stake in Bio‑Techne by 2.4% in Q3, selling 24,946 shares and retaining 1,027,331 shares valued at about $57.15 million (≈0.66% of the company).
• Several large institutions were net buyers—most notably Wellington Management boosted its position by 349.8% to 5,115,133 shares—and institutional investors now own roughly 98.95% of the stock.
• Bio‑Techne recently beat quarterly estimates (EPS $0.46 vs. $0.43; revenue $295.9M vs. $290.2M), trades near $50.85 with a $7.96B market cap, and carries an average analyst price target of $72.77 (consensus: "Moderate Buy").

Aristotle Atlantic Partners LLC trimmed its stake in Bio-Techne Corp (NASDAQ:TECH - Free Report) by 2.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,027,331 shares of the biotechnology company's stock after selling 24,946 shares during the period. Bio-Techne comprises 1.7% of Aristotle Atlantic Partners LLC's investment portfolio, making the stock its 16th biggest holding. Aristotle Atlantic Partners LLC owned approximately 0.66% of Bio-Techne worth $57,150,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in TECH. Wellington Management Group LLP boosted its position in shares of Bio-Techne by 349.8% during the 3rd quarter. Wellington Management Group LLP now owns 5,115,133 shares of the biotechnology company's stock worth $284,555,000 after purchasing an additional 3,978,026 shares during the period. Invesco Ltd. increased its holdings in Bio-Techne by 7.7% in the 3rd quarter. Invesco Ltd. now owns 3,946,028 shares of the biotechnology company's stock valued at $219,518,000 after purchasing an additional 283,303 shares during the last quarter. Neuberger Berman Group LLC raised its position in Bio-Techne by 32.3% in the third quarter. Neuberger Berman Group LLC now owns 3,307,116 shares of the biotechnology company's stock valued at $183,975,000 after purchasing an additional 807,147 shares during the period. DF Dent & Co. Inc. raised its position in Bio-Techne by 2.1% in the third quarter. DF Dent & Co. Inc. now owns 2,780,961 shares of the biotechnology company's stock valued at $154,705,000 after purchasing an additional 56,219 shares during the period. Finally, Champlain Investment Partners LLC lifted its stake in Bio-Techne by 8.9% during the second quarter. Champlain Investment Partners LLC now owns 2,665,684 shares of the biotechnology company's stock worth $137,149,000 after purchasing an additional 217,362 shares in the last quarter. 98.95% of the stock is currently owned by institutional investors and hedge funds.

Bio-Techne Stock Down 1.2%

Bio-Techne stock opened at $50.85 on Friday. Bio-Techne Corp has a twelve month low of $46.01 and a twelve month high of $72.16. The stock's fifty day simple moving average is $62.23 and its 200-day simple moving average is $59.91. The company has a current ratio of 4.54, a quick ratio of 3.08 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $7.96 billion, a P/E ratio of 99.71, a P/E/G ratio of 3.38 and a beta of 1.48.

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.03. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.The firm had revenue of $295.88 million during the quarter, compared to analyst estimates of $290.20 million. During the same period last year, the business posted $0.42 earnings per share. Bio-Techne's revenue was down .4% compared to the same quarter last year. As a group, equities analysts expect that Bio-Techne Corp will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 27th. Stockholders of record on Monday, February 16th were paid a $0.08 dividend. This represents a $0.32 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Friday, February 13th. Bio-Techne's dividend payout ratio (DPR) is presently 62.75%.

Wall Street Analyst Weigh In

Several research firms have recently commented on TECH. TD Cowen restated a "buy" rating and set a $80.00 price target (up from $70.00) on shares of Bio-Techne in a research report on Thursday, February 5th. Zacks Research upgraded Bio-Techne from a "strong sell" rating to a "hold" rating in a report on Monday, February 9th. Robert W. Baird set a $70.00 target price on Bio-Techne in a research note on Thursday, February 5th. UBS Group restated a "buy" rating and set a $79.00 target price (up from $70.00) on shares of Bio-Techne in a report on Thursday, February 5th. Finally, Stifel Nicolaus set a $65.00 target price on Bio-Techne and gave the company a "hold" rating in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $72.77.

Bio-Techne Profile

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.